DOW JONES23,229.55+575.69 2.54%
S&P 5002,721.41+62.00 2.33%
NASDAQ8,030.77+143.51 1.82%

HC Wainwright & Co. Maintains Buy on Stemline Therapeutics, Lowers Price Target to $18

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Stemline Therapeutics (NASDAQ:STML) with a Buy and lowers the price target from $20 to $18.

Benzinga · 03/17/2020 11:28

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Stemline Therapeutics (NASDAQ:STML) with a Buy and lowers the price target from $20 to $18.